Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European ppulations
©2012 AACR..
BACKGROUND: Individuals with higher blood 25-hydroxyvitamin D [25(OH)D] levels have a lower risk of developing colorectal cancer (CRC), but the influence of 25(OH)D on mortality after CRC diagnosis is unknown.
METHODS: The association between prediagnostic 25(OH)D levels and CRC-specific (N = 444) and overall mortality (N = 541) was prospectively examined among 1,202 participants diagnosed with CRC between 1992 and 2003 in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Multivariable Cox proportional hazards models were used to calculate HRs and corresponding 95% CIs according to 25(OH)D quintiles and genetic variation within the VDR and CASR genes. Potential dietary, lifestyle, and metabolic effect modifiers were also investigated.
RESULTS: There were 541 deaths, 444 (82%) due to CRC. Mean follow-up was 73 months. In multivariable analysis, higher 25(OH)D levels were associated with a statistically significant reduction in CRC-specific (P(trend) = 0.04) and overall mortality (P(trend) = 0.01). Participants with 25(OH)D levels in the highest quintile had an adjusted HR of 0.69 (95% CI: 0.50-0.93) for CRC-specific mortality and 0.67 (95% CI: 0.50-0.88) for overall mortality, compared with the lowest quintile. Except for a possible interaction by prediagnostic dietary calcium intake (P(interaction) = 0.01), no other potential modifying factors related to CRC survival were noted. The VDR (FokI and BsmI) and CASR (rs1801725) genotypes were not associated with survival.
CONCLUSIONS: High prediagnostic 25(OH)D levels are associated with improved survival of patients with CRC.
IMPACT: Our findings may stimulate further research directed at investigating the effects of blood vitamin D levels before, at, and after CRC diagnosis on outcomes in CRC patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 21(2012), 4 vom: 14. Apr., Seite 582-93 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
1406-16-2 |
|---|
| Anmerkungen: |
Date Completed 28.08.2012 Date Revised 10.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1158/1055-9965.EPI-11-1065 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM214875016 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM214875016 | ||
| 003 | DE-627 | ||
| 005 | 20231224024424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1055-9965.EPI-11-1065 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0716.xml |
| 035 | |a (DE-627)NLM214875016 | ||
| 035 | |a (NLM)22278364 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fedirko, Veronika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European ppulations |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.08.2012 | ||
| 500 | |a Date Revised 10.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2012 AACR. | ||
| 520 | |a BACKGROUND: Individuals with higher blood 25-hydroxyvitamin D [25(OH)D] levels have a lower risk of developing colorectal cancer (CRC), but the influence of 25(OH)D on mortality after CRC diagnosis is unknown | ||
| 520 | |a METHODS: The association between prediagnostic 25(OH)D levels and CRC-specific (N = 444) and overall mortality (N = 541) was prospectively examined among 1,202 participants diagnosed with CRC between 1992 and 2003 in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Multivariable Cox proportional hazards models were used to calculate HRs and corresponding 95% CIs according to 25(OH)D quintiles and genetic variation within the VDR and CASR genes. Potential dietary, lifestyle, and metabolic effect modifiers were also investigated | ||
| 520 | |a RESULTS: There were 541 deaths, 444 (82%) due to CRC. Mean follow-up was 73 months. In multivariable analysis, higher 25(OH)D levels were associated with a statistically significant reduction in CRC-specific (P(trend) = 0.04) and overall mortality (P(trend) = 0.01). Participants with 25(OH)D levels in the highest quintile had an adjusted HR of 0.69 (95% CI: 0.50-0.93) for CRC-specific mortality and 0.67 (95% CI: 0.50-0.88) for overall mortality, compared with the lowest quintile. Except for a possible interaction by prediagnostic dietary calcium intake (P(interaction) = 0.01), no other potential modifying factors related to CRC survival were noted. The VDR (FokI and BsmI) and CASR (rs1801725) genotypes were not associated with survival | ||
| 520 | |a CONCLUSIONS: High prediagnostic 25(OH)D levels are associated with improved survival of patients with CRC | ||
| 520 | |a IMPACT: Our findings may stimulate further research directed at investigating the effects of blood vitamin D levels before, at, and after CRC diagnosis on outcomes in CRC patients | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a CASR protein, human |2 NLM | |
| 650 | 7 | |a Receptors, Calcitriol |2 NLM | |
| 650 | 7 | |a Receptors, Calcium-Sensing |2 NLM | |
| 650 | 7 | |a Vitamin D |2 NLM | |
| 650 | 7 | |a 1406-16-2 |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 650 | 7 | |a 25-hydroxyvitamin D |2 NLM | |
| 650 | 7 | |a A288AR3C9H |2 NLM | |
| 700 | 1 | |a Riboli, Elio |e verfasserin |4 aut | |
| 700 | 1 | |a Tjønneland, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Olsen, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Bueno-de-Mesquita, H Bas |e verfasserin |4 aut | |
| 700 | 1 | |a van Duijnhoven, Fränzel J B |e verfasserin |4 aut | |
| 700 | 1 | |a Norat, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Eugène H J M |e verfasserin |4 aut | |
| 700 | 1 | |a Dahm, Christina C |e verfasserin |4 aut | |
| 700 | 1 | |a Overvad, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Boutron-Ruault, Marie-Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Clavel-Chapelon, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Racine, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Lukanova, Annekatrin |e verfasserin |4 aut | |
| 700 | 1 | |a Teucher, Birgit |e verfasserin |4 aut | |
| 700 | 1 | |a Boeing, Heiner |e verfasserin |4 aut | |
| 700 | 1 | |a Aleksandrova, Krasimira |e verfasserin |4 aut | |
| 700 | 1 | |a Trichopoulou, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Benetou, Vassiliki |e verfasserin |4 aut | |
| 700 | 1 | |a Trichopoulos, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Grioni, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Vineis, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Panico, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Palli, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Tumino, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Siersema, Peter D |e verfasserin |4 aut | |
| 700 | 1 | |a Peeters, Petra H |e verfasserin |4 aut | |
| 700 | 1 | |a Skeie, Guri |e verfasserin |4 aut | |
| 700 | 1 | |a Brustad, Magritt |e verfasserin |4 aut | |
| 700 | 1 | |a Chirlaque, Maria-Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Barricarte, Aurelio |e verfasserin |4 aut | |
| 700 | 1 | |a Ramón Quirós, Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Maria José |e verfasserin |4 aut | |
| 700 | 1 | |a Dorronsoro, Miren |e verfasserin |4 aut | |
| 700 | 1 | |a Bonet, Catalina |e verfasserin |4 aut | |
| 700 | 1 | |a Palmqvist, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Hallmans, Göran |e verfasserin |4 aut | |
| 700 | 1 | |a Key, Timothy J |e verfasserin |4 aut | |
| 700 | 1 | |a Crowe, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Khaw, Kay-Tee |e verfasserin |4 aut | |
| 700 | 1 | |a Wareham, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Romieu, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a McKay, James |e verfasserin |4 aut | |
| 700 | 1 | |a Wark, Petra A |e verfasserin |4 aut | |
| 700 | 1 | |a Romaguera, Dora |e verfasserin |4 aut | |
| 700 | 1 | |a Jenab, Mazda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology |d 1992 |g 21(2012), 4 vom: 14. Apr., Seite 582-93 |w (DE-627)NLM012651702 |x 1538-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2012 |g number:4 |g day:14 |g month:04 |g pages:582-93 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1055-9965.EPI-11-1065 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2012 |e 4 |b 14 |c 04 |h 582-93 | ||